Anti-VEGF Therapy in Cancer : A Double-Edged Sword

@inproceedings{Gardner2017AntiVEGFTI,
  title={Anti-VEGF Therapy in Cancer : A Double-Edged Sword},
  author={Victor Gardner and Chikezie O. Madu and Yi Lu},
  year={2017}
}
Vascular endothelial growth factor (VEGF) is a mitogen that plays a crucial role in angiogenesis and lymphangiogenesis. It is involved in tumor survival through inducing tumor angiogenesis and by increasing chemoresistance through autocrine signaling. Because of its importance in tumor formation and survival, several medications have been developed to inhibit VEGF and reduce blood vessel formation in cancer. Although these medications have proven to be effective for late-stage and metastatic… CONTINUE READING

Citations

Publications citing this paper.

References

Publications referenced by this paper.
Showing 1-10 of 115 references

Antiangiogenic therapy in oncology : current status and future directions

G Jayson, R Kerbel
The Lancet • 2016

Antiangiogenic therapy in oncology: current status and future directions. The Lancet

G Jayson, R Kerbel
2016

Notch signaling. Cold Spring Harbor Perspectives in Biology

R. Kopan
2016

CYRAMZA is a human, monoclonal antibody that specifically blocks activation of vascular endothelial growth factor (VEGF) Receptor 2 [Internet

R. Lilly
Available from: http://www.cyramzahcp.com/lung/mechanism-of-action.html • 2015

Similar Papers

Loading similar papers…